Recent Advances in Rapid Antimicrobial Susceptibility Testing.

Autor: Datar R; bioMérieux, Microbiology Research, La Balme Les Grottes, France., Orenga S; bioMérieux, Microbiology Research, La Balme Les Grottes, France., Pogorelcnik R; bioMérieux, EU Data Science, Marcy L'Etoile, France., Rochas O; bioMérieux, Corporate Business Development, Marcy l'Etoile, France., Simner PJ; Department of Pathology, Bacteriology, Division of Medical Microbiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA., van Belkum A; bioMérieux, Open Innovation and Partnerships, La Balme Les Grottes, France.
Jazyk: angličtina
Zdroj: Clinical chemistry [Clin Chem] 2021 Dec 30; Vol. 68 (1), pp. 91-98.
DOI: 10.1093/clinchem/hvab207
Abstrakt: Background: Antimicrobial susceptibility testing (AST) is classically performed using growth-based techniques that essentially require viable bacterial matter to become visible to the naked eye or a sophisticated densitometer.
Content: Technologies based on the measurement of bacterial density in suspension have evolved marginally in accuracy and rapidity over the 20th century, but assays expanded for new combinations of bacteria and antimicrobials have been automated, and made amenable to high-throughput turn-around. Over the past 25 years, elevated AST rapidity has been provided by nucleic acid-mediated amplification technologies, proteomic and other "omic" methodologies, and the use of next-generation sequencing. In rare cases, AST at the level of single-cell visualization was developed. This has not yet led to major changes in routine high-throughput clinical microbiological detection of antimicrobial resistance.
Summary: We here present a review of the new generation of methods and describe what is still urgently needed for their implementation in day-to-day management of the treatment of infectious diseases.
(© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze: MEDLINE